Huvudägaren Stena Adactums budpliktsbud på 50 kronor per aktie i Svedbergs framstår i våra ögon som ...
Redeye states that last night’s oral hearing involved reinstated hope in surviving the ‘993 IPR thro...
We give a brief comment on the new clinical study with Vicore’s C21.
Redeye endorses ISAB signing yet another IRS contract worth around SEK 773,000 (EUR 74,000).
Flexion Mobile ökar omsättningen och lönsamheten under året.
Redeye leaves its Base Case unchanged following Infracom’s Q4 report, implying significant upside po...
Redeye raises its Base Case and forecasts following a Q4 report beating our estimates.
Redeye comments on Energy Save’s Q3’21/22 report. The report showed strong growth and profitability ...
Redeye ceases its coverage of Kebni due to the end of the contractual period.
Scandinavian Medical Solutions A/S (“SMS” or the “Company”) is a broker, specialized in the purchase...
SameSystem (“SameSystem” or the “Company”) is a Danish work-force management company “WFM”, the Comp...
Carbiotix AB (”Carbiotix” eller ”Bolaget”) tar fortsatta kliv mot sin bredare kommersiella fas där n...
Adverty enters into an exclusive agreement with Super League Gaming and gains access to more than 15...
Redeye gives a short comment on the announced rights issue of approximately SEK 150m.
Redeye retains its positive view on Speqta following the Strategic Review.
Redeye endorses aXichem receiving yet another aXivite order from its Polish distributor BART.
Kostnaderna tickade upp Rapporten för Q4 2021 summerade ett händelserikt kvartal, där den kliniska p...
Redeye retains its positive view on Transtema following the acquisition of Tessta Connect.
Redeye leaves a comment on InDex Pharmaceuticals following its Capital Markets Day, where the compan...
Modus Therapeutics Holding AB (Modus or the Company) has developed a compound that can revolutionise...
